STOCK TITAN

OSR Health grants Chairman Hwang 1.17M shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

OSR Health, Inc. (OSRH) reported that Chairman Kuk Hyoun Hwang was granted an award of 1,173,697 shares of Common Stock on October 29, 2026, issuable under the 2025 Omnibus Incentive Plan to settle accrued unpaid salary. The award price was $0.2272 per share, equal to 115% of the common stock’s volume-weighted average price for the 15 trading days ended October 28, 2026; the shares are subject to a six-month contractual lock-up from the grant date. Hwang reported 1,173,697 direct shares after the award. Shares held by BCM Europe AG were reported as 8,612,636; Bellevue Capital Management LLC held 3,123,970, and Bellevue Global Life Sciences Investors LLC held 1,332,500. Hwang may be deemed to beneficially own those entities’ shares through his control of them, but disclaims beneficial ownership except to the extent of his pecuniary interest.

Insider Hwang Kuk Hyoun
Role Chairman & Chief Executive Off
Type Security Shares Price Value
Grant/Award OSRH F1 1,173,697 $0.2272 $267K
Holding OSRH F2 -- -- --
Holding OSRH F2 -- -- --
Holding OSRH F2 -- -- --
Holdings After Transaction: OSRH — 1,173,697 shares (Direct); OSRH — 8,612,636 shares (Indirect, By BCM Europe AG); OSRH — 3,123,970 shares (Indirect, By Bellevue Capital Management LLC); OSRH — 1,332,500 shares (Indirect, By Bellevue Global Life Sciences Investors LLC)
Holdings Before and After: OSRH, 0 to 1,173,697 shares (Direct)
Footnotes (2)
  1. F1. Represents shares of Common Stock issuable under the OSR Health, Inc. 2025 Omnibus Incentive Plan in settlement of accrued unpaid salary, at a price per share of $0.2272, equal to 115% of the volume-weighted average price of the Common Stock for the 15 trading days ended October 28, 2026. The award was approved by the Issuer's Board of Directors and Compensation Committee and is exempt under Rule 16b-3(d). The shares are subject to a six-month contractual lock-up from the grant date.
  2. F2. The reporting person may be deemed to beneficially own the shares held by BCM Europe AG, Bellevue Capital Management LLC and Bellevue Global Life Sciences Investors LLC by virtue of his control of such entities. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Award shares 1,173,697 shares Award on October 29, 2026, under the 2025 Omnibus Incentive Plan to settle accrued unpaid salary.
Award price $0.2272 per share Equal to 115% of the common stock’s volume-weighted average price for the 15 trading days ended October 28, 2026.
Direct shares after award 1,173,697 shares Hwang’s reported direct holdings following the October 29, 2026 award.
Shares held by BCM Europe AG 8,612,636 shares Reported as an indirect holding; Hwang disclaimed beneficial ownership except to the extent of his pecuniary interest.
Shares held by Bellevue Capital Management LLC 3,123,970 shares Reported as an indirect holding; Hwang disclaimed beneficial ownership except to the extent of his pecuniary interest.
Shares held by Bellevue Global Life Sciences Investors LLC 1,332,500 shares Reported as an indirect holding; Hwang disclaimed beneficial ownership except to the extent of his pecuniary interest.
2025 Omnibus Incentive Plan financial
"shares of Common Stock issuable under the 2025 Omnibus Incentive Plan"
An omnibus incentive plan is a company-wide program that authorizes awards of pay tied to performance and retention—such as stock options, restricted shares, cash bonuses and other rewards—here labeled for the year it was adopted (2025). Investors care because it affects how much ownership can be issued, dilutes existing shareholders, and aligns executives’ and employees’ incentives with company goals, similar to giving team members a stake in the outcome.
volume-weighted average price financial
"115% of the volume-weighted average price of the Common Stock"
Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.
Rule 16b-3(d) regulatory
"The award is exempt under Rule 16b-3(d)"
Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.
contractual lock-up technical
"subject to a six-month contractual lock-up from the grant date"
A contractual lock-up is an agreement that prevents certain shareholders from selling or transferring their shares for a specified period after a corporate event, such as an initial public offering or a merger. It matters to investors because it temporarily limits how many shares can come onto the market—think of it as a timed lockbox—and when the restriction ends there can be added selling pressure that may affect the stock's supply and price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many OSRH shares did Kuk Hyoun Hwang receive in the award?

The award covered 1,173,697 shares of Common Stock, issuable under the 2025 Omnibus Incentive Plan to settle accrued unpaid salary.

What was the per-share price for Kuk Hyoun Hwang’s OSRH award?

The award price was $0.2272 per share, equal to 115% of the common stock’s volume-weighted average price for the 15 trading days ended October 28, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hwang Kuk Hyoun

(Last)(First)(Middle)
10900 NE 4TH STREET, SUITE 2300

(Street)
BELLEVUE WASHINGTON 98004

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
OSR Health, Inc. [ OSRH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
Chairman & Chief Executive Off
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
10/29/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
OSRH10/29/2026A1,173,697A$0.2272(1)1,173,697D
OSRH8,612,636IBy BCM Europe AG(2)
OSRH3,123,970IBy Bellevue Capital Management LLC(2)
OSRH1,332,500IBy Bellevue Global Life Sciences Investors LLC(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares of Common Stock issuable under the OSR Health, Inc. 2025 Omnibus Incentive Plan in settlement of accrued unpaid salary, at a price per share of $0.2272, equal to 115% of the volume-weighted average price of the Common Stock for the 15 trading days ended October 28, 2026. The award was approved by the Issuer's Board of Directors and Compensation Committee and is exempt under Rule 16b-3(d). The shares are subject to a six-month contractual lock-up from the grant date.
2. The reporting person may be deemed to beneficially own the shares held by BCM Europe AG, Bellevue Capital Management LLC and Bellevue Global Life Sciences Investors LLC by virtue of his control of such entities. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
/s/ Kuk Hyoun Hwang11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading